CN-122005823-A - Application of plant-derived exosome as carrier in preparation of targeted colitis treatment medicament

Abstract

The invention provides application of a plant source exosome as a carrier in preparing a targeted colitis treatment medicament, overcomes the defects of low oral bioavailability and poor gastrointestinal stability of chicoric acid by loading the chicoric acid in an ultraviolet exosome, realizes colon targeting and accumulation of the medicament, provides an ideal functional carrier and candidate preparation for developing a novel anti-colitis nano medicament with high efficiency and low toxicity, and opens up an innovative path for deep processing and industrial chain extension of Yunnan purple rice resources.

Inventors

• WANG YUDAN
• ZHANG LINJING
• CHENG GUIGUANG
• LI GANPENG

Assignees

• 云南民族大学

Dates

Publication Date

20260512

Application Date

20260401

Claims (3)

1. 1. Application of plant source exosomes as carriers in preparing targeted colitis treatment medicines.
2. 2. The method according to claim 1, wherein the drug is chicoric acid.
3. 3. The method according to claim 1, wherein the washed and crushed purple rice flour is added into PBS buffer solution with pH of 6-7.4 for high-speed homogenization, alpha-amylase is added into rice pulp, enzymolysis is carried out for 1-2 hours at pH of 6-7.4 and 90-97 ℃, filtration is carried out, filtrate is kept stand overnight, gradient differential centrifugation is carried out at 4 ℃, supernatant fluid is collected, after filtration, filtrate is subjected to ultracentrifugation for 1.5-3 hours at 4 ℃ and 12000-15000 g, sediment is collected, sediment is resuspended and concentrated by MWCO ultrafiltration tube with molecular weight cut-off of 100kDa, sediment at the bottom of the ultrafiltration tube is collected, and the sediment is resuspended in PBS buffer solution, thus obtaining the plant-derived exosome.

Description

Application of plant-derived exosome as carrier in preparation of targeted colitis treatment medicament Technical Field The invention relates to the technical field of biological medicines, in particular to application of an apoplast as a carrier in preparing a targeted colitis treatment medicament. Background Colitis, particularly ulcerative colitis, is a chronic, nonspecific inflammatory disease affecting the mucous membrane of the colon, and is manifested clinically by abdominal pain, diarrhea, mucopurulent bloody stool, etc. In recent years, along with changes of life style and dietary structure, the incidence of colitis has a rising trend year by year in the global scope, and has the characteristics of long disease course, easy recurrence, high risk of cancer and the like, seriously influences the life quality of patients, and has become a research hotspot in the field of digestive system diseases. Currently, the drugs used clinically to treat colitis mainly include aminosalicylic acids, glucocorticoids, immunosuppressants, biological agents, and the like. However, these treatments have many limitations, including lack of specificity in the in vivo distribution of the drug, difficulty in achieving effective concentrations in the upper stomach and small intestine after oral administration, poor therapeutic effects, systemic side effects such as immunosuppression, metabolic disorders, increased risk of infection, etc. due to long-term use of hormones and immunosuppressants, and expensive biological agents, and primary or secondary unresponsiveness in some patients. Therefore, the development of a drug delivery system capable of realizing colon targeted delivery, improving local drug concentration and reducing systemic toxic and side effects has important clinical significance. In recent years, exosomes have been attracting attention in the field of drug delivery as a naturally derived nanoscale vesicle due to its good biocompatibility, low immunogenicity and natural targeting ability. Compared with exosomes of mammal origin, the exosomes of plant origin (such as exosomes like nano vesicles derived from edible plants such as grapefruit, ginger, lemon and the like) have the advantages of wide sources, low extraction cost, no ethical disputes, and being rich in natural active ingredients and the like. Research shows that part of the plant-derived exosomes have certain biological functions of resisting inflammation, regulating intestinal flora and repairing intestinal mucosa barrier, and are ideal carriers for constructing a colonitis targeting drug delivery system. Therefore, how to construct a drug delivery system with good biocompatibility, natural targeting capability and high-efficiency drug carrying performance by utilizing the natural advantages of the plant-derived exosomes, and to realize the accurate targeted treatment of the colonitis part is a technical problem to be solved in the field. Disclosure of Invention The invention provides a new application of a plant source exosome, namely an application of the plant source exosome in preparing a medicament for targeted treatment of colonitis, by precisely controlling the mass ratio of the medicament to the exosome, on the premise of ensuring the structural integrity and targeting of exosomes, the targeted delivery of drug load and colon inflammation parts is realized, and a safe and effective new strategy is provided for the treatment of colonitis. The invention relates to a method for preparing a plant source exosome by referring to patent application 202511343447.3, which comprises the steps of adding cleaned and crushed purple rice flour into PBS buffer solution with pH of 6-7.4, homogenizing at high speed, adding alpha-amylase into rice pulp, carrying out enzymolysis for 1-2 h at pH of 6-7.4 and 90-97 ℃, filtering, standing filtrate overnight, carrying out gradient differential centrifugation at 4 ℃, collecting supernatant, carrying out ultracentrifugation on the filtrate at 4 ℃ for 1.5-3 h at 12000-15000 g, collecting precipitate, carrying out concentration by using MWCO ultrafiltration tube with molecular weight cutoff of 100kDa, collecting precipitate at the bottom of the ultrafiltration tube, and carrying out resuspension in the PBS buffer solution to obtain the plant source exosome. Mixing the medicine with the plant source exosome solution according to a certain proportion, wrapping the medicine in the plant source exosome by an ultrasonic co-incubation method or a co-incubation method, and removing the non-wrapped medicine by adopting a 100kDa MWCO ultrafiltration tube to obtain the medicine for targeted treatment of colonitis. The ultrasonic co-incubation method is to mix the drug with the solution of the explant, carry out ultrasonic treatment for 30s at 1% -20% of amplitude, then pause for 3min, circulate for 5-10 times, then incubate for 1-3h at 37 ℃, then place for 4 ℃ for standing overnight, thus completing the drug encapsulation, an